INSIGHTS ON SOLID DOSE MANUFACTURING
-
A Technology Driven CDMO & Trusted Manufacturing Partner
Whether it's through extended release formulations or titratable dosage forms, we are dedicated to addressing the specific needs of different patient populations, including pediatrics and geriatrics.
-
Technologies And Patient-Centric Solutions
Our innovative technology platforms, including Taste Masked Microcaps® and Optimµm®, address issues like taste masking, swallowability, and controlled release to improve patients' quality of life.
-
Low-Bioburden Powders For Terminal Sterilisation
Low‑bioburden powders for reconstitution demand strict microbial control, advanced formulation, and specialised manufacturing, making CDMO expertise vital for modern biopharma.
-
Orally-Disintegrating Dosage Forms With Taste Masked Multiparticulates
Learn more about our orally disintegrating tablet (ODT) capabilities and how these innovative technologies have the potential to improve acceptance, adherence, and compliance in pharmacotherapy.
-
Improving API Solubility Using Hot Melt Extrusion Formulation2/27/2025
Solubility of active pharmaceutical ingredients (APIs) is a challenge in drug development. Discover how hot melt extrusion with polyvinyl alcohol enhances API solubility and stability to offer improved drug delivery.
-
Overload Setting – Tricks And Techniques9/23/2024
Learn how a partner company that is committed to assisting manufacturers with calibration and optimal set-point establishment can serve as a valuable resource in achieving optimal tablet production.
-
Isolators For Pharmacy Compounding – Time For Change?3/14/2025
Maintaining a contamination-free environment is crucial in drug compounding. Learn how isolator systems can improve safety, efficiency, and regulatory compliance.
-
5 Advancements In Tablet Compression That Pharma Can't Ignore In 202611/4/2025
New materials, smart automation, and in-press quality control are optimizing tablet compression. These five key innovations are driving efficiency and consistency in solid dose manufacturing today.
-
Innovations, Solutions, And USP <1062> With Scale Up11/4/2025
Optimize tablet compression by simplifying calibration, speeding up changeovers, and utilizing advanced laser inspection to prevent critical punch tip wear and maintain quality.
SOLID DOSE MANUFACTURING SOLUTIONS
-
The aseptic/sterile Fill-Finish equipment solutions need to be cGMP compliant, dependable and accurately designed to comply with the most recent revisions of the “Annex 1 Manufacture of Sterile Medicinal Products guidelines”. Newly designed equipment needs to accommodate for small batches, various speeds and containers, including RTU / RTF (Ready To Use or Ready To Fill) bottles, vials, cartridges, syringes and pre-sterile nested trays. Moreover, the filling equipment solution should also improve the ergonomic use for operators and maximize cleanroom efficiency.
-
Closed RABS as a housing for aseptic processes, e.g., filling, loading, and unloading of freeze dryers. Product protection is achieved through a barrier (cRABS housing with gloves) between the operator and the product.
-
Used IMA Zanasi 6 F Capsule Filler, rated up to 6000 capsules/hour, no change parts, capable of producing 00-5 size capsules, with controls and Siemens PLC, 230 volt, 3 phase, serial# 35071, built 2006.
-
Used Fuji Paudal Marumerizer spheronizer, model QJ700, stainless steel construction, with 2.0 mm grooved spheronizing plate with plate lift mechanism, jacketed bowl, side discharge with pneumatically operated plug valve, on base, serial 20050, built 1990.
-
Partner with Natoli Scientific during the earliest stages. Our scientific expertise with state-of-the-art analytical capabilities is ready to take any preformulation challenge.
Natoli scientific has an expertise of handling a wide range of APIs for the development of oral solids. We apply principles of ‘Quality by Design’ to define Critical Material Attributes (CMA), Critical Process Parameters (CPP), Critical Quality Attributes (CQA) and Quality Target Product Profiles (QTPP). Because we believe that understanding material and process as much as possible in the early life cycle of drug product development program is an insurance for further development path. Keeping your practices up to date with the ICHQ8 regulatory guidance issued by the US FDA. This is also a gate way for a smooth ride of product in the different stages of product development stages.